NCT04468061: Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have metastatic breast cancer that is PD-L1-negative
Exclusions: Patients that have received any treatments in the metastatic setting; Patients with unstable untreated symptomatic brain metastases – see trial for details

Comments are closed.

Up ↑